Gemini Therapeutics completed enrollment in a phase 2a study investigating safety and tolerability of GEM103 in dry age-related macular degeneration, according to a press release.
ReGAtta is an ongoing, multicenter, open-label, multiple ascending dose study of a recombinant form of the human complement factor H (CFH) protein in patients with dry AMD and CFH loss-of-function gene variants, the release said.
“Our strategy is to provide an intravitreal recombinant human factor H in patients with gene variants resulting in loss of function of their own CFH,” Marc E. Uknis, MD, FACS,
Uncategorized